Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events The ODYSSEY OUTCOMES Trial


Szarek M., White H. D. , Schwartz G. G. , Alings M., Bhatt D. L. , Bittner V. A. , ...Daha Fazla

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, cilt.73, sa.4, ss.387-396, 2019 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 73 Konu: 4
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1016/j.jacc.2018.10.039
  • Dergi Adı: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
  • Sayfa Sayıları: ss.387-396

Özet

BACKGROUND The ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial compared alirocumab with placebo, added to high-intensity or maximum-tolerated statin treatment, after acute coronary syndrome (ACS) in 18,924 patients. Alirocumab reduced the first occurrence of the primary composite endpoint and was associated with fewer all-cause deaths.